Which medication is contraindicated in conjunction with dofetilide due to increased risk of QT prolongation?

Dofetilide is a class III antiarrhythmic medication that can cause significant QT interval prolongation, which increases the risk of life-threatening arrhythmias, particularly torsades de pointes. When considering the combination of dofetilide with other medications, it is important to identify those that also have the potential to prolong the QT interval, as this can exacerbate the risk of serious side effects.

Amiodarone, a potent antiarrhythmic agent, is known to have a direct effect on cardiac repolarization, and it also increases the QT interval. When it is used in conjunction with dofetilide, the risk of developing dangerously prolonged QT interval and subsequent arrhythmias is significantly elevated. Therefore, the combination of these two drugs is contraindicated in clinical practice to mitigate this risk.

In contrast, while metoprolol and furosemide do not have a known significant impact on QT prolongation, sotalol also prolongs the QT interval, but it is a similar class of medication to dofetilide, and caution is warranted; however, the risk with amiodarone is notably higher due to its pharmacokinetic interactions and effects on heart rhythm. Thus, the combination